Vitro Biopharma Inc. entered into definitive agreements with accredited investors for a private placement of a convertible promissory note and warrants to purchase shares of common shares for gross proceeds of $237,600 on March 15, 2023. The note will carry a coupon of 8% per annum, the convertible notes may be converted at any time at the option of the holder and are payable in full at the earliest of the completion of a qualified financing as defined below - a change in control, or an event of default, or the maturity date, which is five years from the date of issuance.
1st Jan change | Capi. | |
---|---|---|
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B | |
-4.33% | 8.5B |